Sees FY26 Operating Expenses at $150M-$160M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy RXST?
Sees FY26 operating expenses $150M-$160M. Sees FY26 gross margin 70%-72%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RXST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RXST
Wall Street analysts forecast RXST stock price to rise
9 Analyst Rating
1 Buy
6 Hold
2 Sell
Hold
Current: 7.610
Low
8.00
Averages
10.25
High
14.00
Current: 7.610
Low
8.00
Averages
10.25
High
14.00
About RXST
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RxSight, Inc. Reports Q4 2025 Earnings with Strategic Insights
- Sales Performance Review: RxSight reported Q4 2025 sales of $32.6 million, a 19% year-over-year decline primarily due to lower LDD sales, although LAL sales accounted for 86% of total sales, indicating strong demand for its core products.
- Financial Condition Analysis: The company recorded a net loss of $9.2 million in Q4 2025, translating to a loss of $0.22 per share, and while SG&A expenses decreased by 2% year-over-year, the overall financial performance remains under pressure, reflecting intensified market competition and rising costs.
- Future Outlook Guidance: Management anticipates 2026 revenue between $120 million and $135 million, implying a year-over-year decline of approximately 5% at the midpoint, with gross margin guidance set at 70% to 72%, demonstrating a cautious approach to the future market environment.
- Strategic Development Direction: Management emphasized a focus on enhancing LAL utilization among existing customers and building relationships with key opinion leaders in international markets to support future sales growth, despite the risks associated with declining LDD sales.
See More
RxSight Issues 2026 Financial Guidance with Q4 Results
- Earnings Highlights: RxSight reported a Q4 non-GAAP EPS of -$0.03, beating expectations by $0.17, indicating an improvement in profitability despite an 18.9% year-over-year revenue decline to $32.6 million, reflecting ongoing market demand challenges.
- 2026 Financial Guidance: The company projects 2026 revenue between $120 million and $135 million, reflecting lower year-over-year LDD placements, which highlights the challenges in the market environment and a cautious outlook for future growth.
- Gross Margin Expectations: The anticipated gross margin for 2026 is set at 70% to 72%, primarily driven by increased per-unit manufacturing costs, which could impact overall profitability, especially with declining production volumes.
- Operating Expense Outlook: The company expects operating expenses for 2026 to range from $150 million to $160 million, with non-cash stock-based compensation expenses projected at $30 million to $32 million, indicating pressure on cost control while also reflecting a commitment to future investments.
See More
U.S. Stocks Mixed; Day One Biopharmaceuticals Shares Surge 20%
- Mixed Market Performance: U.S. stocks exhibited mixed results on Monday, with the Nasdaq Composite gaining over 50 points and rising 0.29%, while the Dow Jones fell 0.19% to 49,411.94, indicating market volatility and investor caution.
- Biopharma Surge: Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares surged 20% to $10.77 after reporting a projected 2025 OJEMDA net product revenue of $155.4 million, a 172% year-over-year increase, highlighting strong market demand and growth potential.
- FDA Response Impact: Atara Biotherapeutics Inc (NASDAQ:ATRA) shares plummeted 53% to $6.41 following a Complete Response Letter from the FDA citing concerns over clinical trial adequacy, raising investor worries about the company's future prospects.
- Sector Sentiment Fluctuations: Financial stocks dipped by 1.1% while consumer staples rose by 1%, reflecting differing investor confidence across sectors, which may influence future investment strategies and market trends.
See More
Planet Labs PBC Secures Nine-Figure Deal with Swedish Armed Forces, Shares Surge 7%
- Stock Surge: Planet Labs PBC's announcement of a multi-year nine-figure agreement with the Swedish Armed Forces led to a 7% increase in share price to $24.29 on Monday, reflecting strong market confidence in the company's long-term contracts.
- Revenue Outlook Boost: Day One Biopharmaceuticals Inc reported preliminary 2025 OJEMDA net product revenue of $155.4 million, up 172% year-over-year, indicating robust growth potential in the biopharmaceutical sector that may attract more investor interest.
- Market Dynamics: Amid a broader decline in U.S. stocks, Wheels Up Experience Inc saw its shares jump 30.2% to $0.89, suggesting a market reassessment of its business model, potentially providing support for future financing and expansion.
- Increased Demand for Safe Assets: Growing concerns about Federal Reserve independence have led investors to shift towards safe-haven assets like gold, driving up precious metals stocks, which reflects market sensitivity to economic uncertainties and a preference for secure investments.
See More
RxSight Expects Q4 2025 Revenue of $32.6 Million, Appoints CFO
- Revenue Forecast Upgrade: RxSight anticipates Q4 2025 revenue to reach approximately $32.6 million, exceeding analysts' expectations of $27.53 million, indicating strong market performance and growth potential for the company.
- Annual Revenue Outlook: Preliminary unaudited revenue for fiscal year 2025 is expected to be around $134.5 million, up from the November guidance of $125 million to $130 million, reflecting robust business growth and increased market demand.
- Executive Appointment: The company has appointed Mark Wilterding as Chief Financial Officer, effective January 11, 2026, bringing over 25 years of financial leadership experience that will provide valuable industry insights and strategic direction.
- Financial Reporting Schedule: RxSight plans to announce audited full-year financial results and 2026 guidance in conjunction with its Q4 earnings release, expected to provide investors with clearer future outlooks.
See More
RxSight Reports $134.5M Revenue for 2025, Announces CFO Transition
- Revenue Growth: Preliminary unaudited revenue for 2025 is expected to be approximately $134.5 million, exceeding prior guidance of $125 to $130 million, indicating strong performance in the ophthalmic medical device market.
- Procedure Volume Increase: The sale of 28,611 Light Adjustable Lenses (LAL) in Q4 represents a 10% increase compared to Q3 2025, reflecting positive progress in surgical volume recovery.
- Device Installation Expansion: As of December 31, 2025, the company has installed 1,134 Light Delivery Devices (LDD), which not only enhances market penetration but also lays a solid foundation for future growth.
- Executive Transition: Mark Wilterding has been appointed Chief Financial Officer effective January 11, 2026, and with his extensive experience in Medtech, he is expected to drive further advancements in financial management and operational excellence for the company.
See More
RxSight, Inc. Reports Q4 2025 Earnings with Strategic Insights
- Sales Performance Review: RxSight reported Q4 2025 sales of $32.6 million, a 19% year-over-year decline primarily due to lower LDD sales, although LAL sales accounted for 86% of total sales, indicating strong demand for its core products.
- Financial Condition Analysis: The company recorded a net loss of $9.2 million in Q4 2025, translating to a loss of $0.22 per share, and while SG&A expenses decreased by 2% year-over-year, the overall financial performance remains under pressure, reflecting intensified market competition and rising costs.
- Future Outlook Guidance: Management anticipates 2026 revenue between $120 million and $135 million, implying a year-over-year decline of approximately 5% at the midpoint, with gross margin guidance set at 70% to 72%, demonstrating a cautious approach to the future market environment.
- Strategic Development Direction: Management emphasized a focus on enhancing LAL utilization among existing customers and building relationships with key opinion leaders in international markets to support future sales growth, despite the risks associated with declining LDD sales.
See More
RxSight Issues 2026 Financial Guidance with Q4 Results
- Earnings Highlights: RxSight reported a Q4 non-GAAP EPS of -$0.03, beating expectations by $0.17, indicating an improvement in profitability despite an 18.9% year-over-year revenue decline to $32.6 million, reflecting ongoing market demand challenges.
- 2026 Financial Guidance: The company projects 2026 revenue between $120 million and $135 million, reflecting lower year-over-year LDD placements, which highlights the challenges in the market environment and a cautious outlook for future growth.
- Gross Margin Expectations: The anticipated gross margin for 2026 is set at 70% to 72%, primarily driven by increased per-unit manufacturing costs, which could impact overall profitability, especially with declining production volumes.
- Operating Expense Outlook: The company expects operating expenses for 2026 to range from $150 million to $160 million, with non-cash stock-based compensation expenses projected at $30 million to $32 million, indicating pressure on cost control while also reflecting a commitment to future investments.
See More
U.S. Stocks Mixed; Day One Biopharmaceuticals Shares Surge 20%
- Mixed Market Performance: U.S. stocks exhibited mixed results on Monday, with the Nasdaq Composite gaining over 50 points and rising 0.29%, while the Dow Jones fell 0.19% to 49,411.94, indicating market volatility and investor caution.
- Biopharma Surge: Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares surged 20% to $10.77 after reporting a projected 2025 OJEMDA net product revenue of $155.4 million, a 172% year-over-year increase, highlighting strong market demand and growth potential.
- FDA Response Impact: Atara Biotherapeutics Inc (NASDAQ:ATRA) shares plummeted 53% to $6.41 following a Complete Response Letter from the FDA citing concerns over clinical trial adequacy, raising investor worries about the company's future prospects.
- Sector Sentiment Fluctuations: Financial stocks dipped by 1.1% while consumer staples rose by 1%, reflecting differing investor confidence across sectors, which may influence future investment strategies and market trends.
See More
Planet Labs PBC Secures Nine-Figure Deal with Swedish Armed Forces, Shares Surge 7%
- Stock Surge: Planet Labs PBC's announcement of a multi-year nine-figure agreement with the Swedish Armed Forces led to a 7% increase in share price to $24.29 on Monday, reflecting strong market confidence in the company's long-term contracts.
- Revenue Outlook Boost: Day One Biopharmaceuticals Inc reported preliminary 2025 OJEMDA net product revenue of $155.4 million, up 172% year-over-year, indicating robust growth potential in the biopharmaceutical sector that may attract more investor interest.
- Market Dynamics: Amid a broader decline in U.S. stocks, Wheels Up Experience Inc saw its shares jump 30.2% to $0.89, suggesting a market reassessment of its business model, potentially providing support for future financing and expansion.
- Increased Demand for Safe Assets: Growing concerns about Federal Reserve independence have led investors to shift towards safe-haven assets like gold, driving up precious metals stocks, which reflects market sensitivity to economic uncertainties and a preference for secure investments.
See More
RxSight Expects Q4 2025 Revenue of $32.6 Million, Appoints CFO
- Revenue Forecast Upgrade: RxSight anticipates Q4 2025 revenue to reach approximately $32.6 million, exceeding analysts' expectations of $27.53 million, indicating strong market performance and growth potential for the company.
- Annual Revenue Outlook: Preliminary unaudited revenue for fiscal year 2025 is expected to be around $134.5 million, up from the November guidance of $125 million to $130 million, reflecting robust business growth and increased market demand.
- Executive Appointment: The company has appointed Mark Wilterding as Chief Financial Officer, effective January 11, 2026, bringing over 25 years of financial leadership experience that will provide valuable industry insights and strategic direction.
- Financial Reporting Schedule: RxSight plans to announce audited full-year financial results and 2026 guidance in conjunction with its Q4 earnings release, expected to provide investors with clearer future outlooks.
See More
RxSight Reports $134.5M Revenue for 2025, Announces CFO Transition
- Revenue Growth: Preliminary unaudited revenue for 2025 is expected to be approximately $134.5 million, exceeding prior guidance of $125 to $130 million, indicating strong performance in the ophthalmic medical device market.
- Procedure Volume Increase: The sale of 28,611 Light Adjustable Lenses (LAL) in Q4 represents a 10% increase compared to Q3 2025, reflecting positive progress in surgical volume recovery.
- Device Installation Expansion: As of December 31, 2025, the company has installed 1,134 Light Delivery Devices (LDD), which not only enhances market penetration but also lays a solid foundation for future growth.
- Executive Transition: Mark Wilterding has been appointed Chief Financial Officer effective January 11, 2026, and with his extensive experience in Medtech, he is expected to drive further advancements in financial management and operational excellence for the company.
See More
